Checkmate Pharmaceuticals (CMPI) Stock Price, News & Analysis

Company Overview

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $10.50 to $10.50
• 50-Day Range: $10.37 to $10.50
• 52-Week Range: $2.00 to $10.50
• Volume: N/A
• Average Volume: 142,261 shs
• Market Capitalization: $231.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CMPI Stock Analysis - Frequently Asked Questions

How were Checkmate Pharmaceuticals' earnings last quarter?

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.02.

When did Checkmate Pharmaceuticals IPO?

Checkmate Pharmaceuticals (CMPI) raised $75 million in an initial public offering on Friday, August 7th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets served as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Checkmate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Checkmate Pharmaceuticals investors own include Athenex (ATNX), KLX Energy Services (KLXE), TherapeuticsMD (TXMD), BioNTech (BNTX), Bolt Biotherapeutics (BOLT), Nabors Industries (NBR) and NGL Energy Partners (NGL).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 6/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CMPI
• CIK: 1651431
• Web: www.checkmatepharma.com
• Phone: 617-682-3625
• Fax: N/A
• Employees: 28
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.40 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -83.92%
• Return on Assets: -74.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.20
• Quick Ratio: 5.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.50 per share
• Price / Book: 4.20

Miscellaneous

• Outstanding Shares: 22,038,000
• Free Float: 8,242,000
• Market Cap: $231.40 million
• Optionable: Not Optionable
• Beta: -4.81